Xinyan Pan
Impact in
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
Papers in
- Oncology 20
- CAR-T cell therapy research 5
- Peptidase Inhibition and Analysis 4
- Cancer Immunotherapy and Biomarkers 3
- Cancer-related Molecular Pathways 3
- Co-authors
- Ju-Lun Yang (17 shared papers)Qiang Feng (16 shared papers)Wei Huo (3 shared papers)Shuling Song (9 shared papers)Min Du (2 shared papers)Xiaomin Zhu (2 shared papers)Wei Gong (1 shared paper)Zhengwen An (1 shared paper)
- Journals
- BMC Cancer (4 papers)Frontiers in Oncology (2 papers)Cancer Biotherapy and Radiopharmaceuticals (2 papers)Molecular Therapy — Oncolytics (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- ChinaUnited StatesSweden
In The Last Decade
Xinyan Pan
37 papers receiving 384 citations
Peers
Comparison fields: 5 of 83
- Cancer Research 97
- Oncology 145
- Molecular Biology 251
- Genetics 64
- Biotechnology 18
Countries citing papers authored by Xinyan Pan
This map shows the geographic impact of Xinyan Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinyan Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinyan Pan more than expected).
Fields of papers citing papers by Xinyan Pan
This network shows the impact of papers produced by Xinyan Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinyan Pan. The network helps show where Xinyan Pan may publish in the future.
Co-authors
The 25 scholars most cited alongside Xinyan Pan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 65 | |
| 2 | 2017 | 42 | |
| 3 | 2012 | 24 | |
| 4 | Prognostic value of ALDH1 expression in lung cancer: a meta-analysis. | 2015 | 20 |
| 5 | 2012 | 19 | |
| 6 | 2018 | 17 | |
| 7 | 2019 | 14 | |
| 8 | 2017 | 13 | |
| 9 | 2016 | 13 | |
| 10 | 2021 | 13 | |
| 11 | 2006 | 13 | |
| 12 | 2019 | 12 | |
| 13 | 2021 | 11 | |
| 14 | 2016 | 11 | |
| 15 | 2014 | 10 | |
| 16 | 2023 | 10 | |
| 17 | 2022 | 10 | |
| 18 | 2018 | 9 | |
| 19 | 2025 | 7 | |
| 20 | 2021 | 6 |
About Xinyan Pan
Xinyan Pan is a scholar working on Oncology, Molecular Biology, Genetics, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 390 indexed citations. Recurring topics across this work include Virus-based gene therapy research (8 papers), CAR-T cell therapy research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Peptidase Inhibition and Analysis (4 papers), Cancer-related molecular mechanisms research (4 papers), Sirtuins and Resveratrol in Medicine (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (97 citations), Oncology (145 citations), Molecular Biology (251 citations), Genetics (64 citations) and Biotechnology (18 citations). Xinyan Pan has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Ju-Lun Yang, Qiang Feng, Wei Huo, Shuling Song, Min Du, Xiaomin Zhu, Wei Gong, Zhengwen An, Bo Jiang and Yunling Wang. Their work appears in journals such as BMC Cancer, Frontiers in Oncology, Cancer Biotherapy and Radiopharmaceuticals, Molecular Therapy — Oncolytics and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.